Document is current
Any future updates will be listed below
-
Authors
Caruso, Irene https://orcid.org/0000-0002-5891-269X
Cignarelli, Angelo https://orcid.org/0000-0001-6477-9031
Sorice, Gian Pio https://orcid.org/0000-0001-9489-1534
Perrini, Sebastio https://orcid.org/0000-0002-2728-7721
Giorgino, Francesco https://orcid.org/0000-0001-7372-2678
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 16 May 2024
First Online: 6 November 2024
Competing interests
: A.C.: AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diagnostics, Sanofi Aventis. F.G.: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Medimmune, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis. G.P.S.: Amgen, Amryt, Eli Lilly, Farmitalia, Novo Nordisk, Sanofi; I.C.: Eli Lilly, Novo Nordisk; S.P.: no competing interests.
